Cellect v. Samsung: Federal Circuit Affirms in Endoscopic Imaging Patent Appeal
Cellect, LLC challenged Samsung Electronics over US9186052B1, directed to reduced area imaging devices incorporated within endoscopes. A per curiam Federal Circuit panel — Judges Lourie, Dyk, and Reyna — affirmed the decision below in an invalidity/cancellation action, closing a 545-day appellate proceeding.
Endoscopic imaging patent survives Samsung challenge at the Federal Circuit
Cellect, LLC filed this appeal at the United States Court of Appeals for the Federal Circuit on 16 December 2021 (case no. 22-1272). The dispute centres on US9186052B1 (application no. US14/705334), which covers a reduced area imaging device incorporated within endoscopic devices — a compact sensor architecture with direct relevance to minimally invasive medical imaging. Samsung Electronics Co., Ltd. and its US subsidiary Samsung Electronics America, Inc. were the appellees, represented by Ropes & Gray, LLP.
The recorded basis of termination is 'Appeal Dismissed'; the docket order states: 'ORDERED and ADJUDGED: PER CURIAM (LOURIE, DYK, and REYNA, Circuit Judges). AFFIRMED.' The verdict cause is recorded as an invalidity/cancellation action under patentability grounds. The specific terms underlying the resolution are not further disclosed in the available record.
The proceeding ran for 545 days from filing to closure on 14 June 2023. A per curiam disposition — issued without a named authoring judge — suggests the panel found the outcome sufficiently clear on the record to forgo an extended written opinion, though no further explanation is available from the public docket. What drove the underlying invalidity challenge and whether any claim-specific arguments were separately addressed remain undisclosed.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 545 days
545-day appellate proceeding — longer than the Federal Circuit median for patent validity appeals
US9186052B1 — Reduced area imaging device for endoscopic applications
Medical device R&D teams and OEMs developing compact imaging modules for endoscopic, laparoscopic, or capsule-based applications should assess their exposure to US9186052B1 and related Cellect assets. Although the Federal Circuit has affirmed an invalidity finding in connection with this patent, the precise scope of invalidated versus surviving claims is not fully disclosed in the public appellate record. Any product team shipping a reduced area sensor in an endoscopic device should not assume full freedom without a formal claim-level analysis.
Official order — verbatim text
The per curiam panel of Judges Lourie, Dyk, and Reyna ordered and adjudged the decision below affirmed without a named authoring opinion. In Federal Circuit practice, a per curiam affirmance in an invalidity/cancellation appeal indicates the panel found the lower tribunal's patentability determination free from reversible legal error on the existing record. The absence of extended written reasoning means the specific invalidity rationale — whether anticipation, obviousness, or another ground — is not independently elaborated at the appellate level, and practitioners must look to the underlying proceeding's record for claim-by-claim analysis.
Federal Circuit affirms: what the ruling means for both parties
What 'AFFIRMED' means at the Federal Circuit
An affirmance by the Federal Circuit means the panel found no reversible error in the decision below. The lower tribunal's ruling — here on patentability/invalidity grounds — stands as issued. A per curiam affirmance, signed collectively rather than by a named judge, typically signals the panel viewed the outcome as legally uncontroversial on the existing record, though no extended reasoning is required by that format.
No reversible error foundCellect's patent survives the Samsung invalidity challenge
For Cellect as appellant, an affirmance is an unfavourable outcome: the invalidity or cancellation ruling from the proceeding below is upheld. US9186052B1's enforceability is constrained by whatever the lower decision determined. Cellect's further appellate options at this level are exhausted; any further challenge would require petition to the Supreme Court, a high bar that is rarely cleared in patent validity disputes.
Lower invalidity ruling upheldSamsung secures affirmance of the invalidity finding
Samsung Electronics and its US subsidiary, as appellees, benefit from the affirmance: the decision invalidating or cancelling the challenged claims of US9186052B1 is now final at the Federal Circuit level. This removes or narrows the patent's threat to Samsung's endoscopic and compact imaging product lines. The ruling also raises the bar for Cellect to reassert equivalent claims in future proceedings.
Invalidity affirmed, patent risk reducedCompact endoscopic imaging IP landscape shifts post-affirmance
A Federal Circuit affirmance of an invalidity finding on a compact imaging patent signals heightened scrutiny of the prior art base in this technology domain. Competitors and device makers working with reduced area imaging sensors in endoscopic applications should monitor the surviving claim scope of US9186052B1 and adjacent Cellect portfolio patents. The affirmance may embolden further validity challenges against related Cellect assets in the endoscopic imaging space.
Endoscopic imaging IP risk recalibratedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cellect, LLC | Company | Medical imaging IP holding company — holder of US9186052B1 covering endoscopic reduced area imaging devicesSearch in Eureka ↗ |
| Defendant | Samsung Electronics Co., Ltd. | Company | Samsung Electronics Co., Ltd. — global consumer electronics and semiconductor manufacturer, and its US subsidiarySearch in Eureka ↗ |
| Co-Defendant | Samsung Electronics America, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jonathan Caplan | Attorney | Counsel for Cellect, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Kramer Levin Naftalis & Frankel, LLP | Law Firm | Representing Cellect, LLCSearch in Eureka ↗ |
| Defendant counsel | Scott Anthony McKeown | Attorney | Counsel for Samsung Electronics Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Ropes & Gray, LLP | Law Firm | Representing Samsung Electronics Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the compact endoscopic imaging IP space
Forward-looking patent intelligence derived from the Cellect v. Samsung Federal Circuit appeal — covering imaging sensor portfolios, filing trends, and white-space opportunities.
Cellect's endoscopic imaging portfolio beyond US9186052B1
Cellect's filing activity in compact and reduced area imaging devices suggests a cluster of related assets sharing the US14/705334 priority chain. R&D and IP teams should map continuation patents, divisionals, and closely related applications to understand whether the invalidity rationale from the Samsung proceeding creates cascading vulnerability across the portfolio or leaves enforceable claim islands.
Cellect portfolio depthFiling trends in miniaturised endoscopic imaging sensors
The compact imaging sensor space for endoscopic devices has seen sustained filing activity from medical device OEMs and semiconductor companies. Monitoring recent PCT and US applications in reduced area CMOS sensor architectures for endoscopy reveals which players are staking out new claim territory — and where prior art density may constrain fresh prosecution strategy.
Endoscopic sensor filing trendsSamsung's patent position in compact endoscopic imaging
Samsung Electronics holds a broad semiconductor and imaging IP portfolio that extends into medical and industrial sensor applications. Following the Federal Circuit affirmance, understanding Samsung's own filed patents in miniaturised imaging and endoscopic sensor integration helps assess whether Samsung is building offensive IP coverage in the space it just successfully defended — a common post-litigation portfolio move.
Samsung imaging IP depthAdjacent claim space after the invalidity finding
An affirmed invalidity ruling can open claim territory that was previously blocked by the asserted patent. R&D teams developing next-generation reduced area imaging architectures — including flexible sensor arrays, single-chip endoscopic modules, or AI-enhanced imaging pipelines — should audit the now-challenged design space for patentable differentiation opportunities that avoid the prior art of record from the Samsung proceedings.
Post-invalidity white spaceSimilar Federal Circuit patent validity appeals in medical imaging
Cases involving patentability challenges to compact medical imaging sensor patents at the Federal Circuit, including endoscopic device IP invalidity appeals.
What this case signals for the medical imaging IP landscape
A Federal Circuit per curiam affirmance in an invalidity action carries weight well beyond the two parties — it shapes enforcement risk across the compact endoscopic sensor sector.
Per curiam affirmances signal weak appellate footing for patent holders
When the Federal Circuit issues a per curiam affirmance in a patentability appeal, it consistently suggests the panel found the invalidity outcome clearly supported by the record. Patent holders in the endoscopic imaging space should audit claim portfolios for similar prior art exposure before pursuing enforcement.
Samsung's appellate success strengthens its compact imaging product freedom
With the invalidity ruling affirmed, Samsung Electronics removes a key IP obstacle in the reduced area imaging device segment. Competitors should note that this outcome may encourage Samsung to expand product lines incorporating compact endoscopic sensors, and may signal further validity challenges against related patents in this space.
Cellect v Samsung — key questions answered
The Federal Circuit issued a per curiam order affirming the decision below. The panel of Judges Lourie, Dyk, and Reyna adjudged the case affirmed in an invalidity/cancellation action concerning US9186052B1. The recorded basis of termination in the docket is 'Appeal Dismissed'; the order text states 'AFFIRMED.' The specific terms and the precise invalidity grounds are not further detailed in the publicly available appellate record.
US9186052B1 (application no. US14/705334) covers a reduced area imaging device incorporated within endoscopic devices — a compact imaging sensor architecture relevant to minimally invasive medical instruments. Samsung Electronics Co., Ltd. and Samsung Electronics America, Inc. were named in the invalidity/cancellation action. The specific product or feature of Samsung's that allegedly fell within or prompted the validity challenge is not disclosed in the available appellate record.
A per curiam affirmance means the three-judge panel collectively affirmed the lower decision without designating a single authoring judge, and without issuing an extended opinion. In Federal Circuit practice this typically signals the panel found the lower tribunal's patentability determination clearly supported by the record and free from reversible legal error. It does not, however, create binding precedent in the same way a named, precedential opinion would.
The affirmance upholds the invalidity or cancellation determination made in the underlying proceeding. However, the precise scope of which claims were invalidated or cancelled is not disclosed in the publicly available appellate record. If any claims survived the underlying proceeding, their enforceability would be unaffected by the appellate ruling. Parties seeking to rely on this outcome for FTO or clearance purposes should review the full record of the proceedings below.
Following a Federal Circuit affirmance, Cellect's further appellate options at the federal court level are limited to a petition for writ of certiorari to the Supreme Court — a remedy that is rarely granted in patent validity cases. Cellect may also consider whether any related patents in its portfolio are not subject to the same invalidity rationale, or whether re-prosecution of related pending applications remains available. The specific strategic options available to Cellect are not disclosed in the public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.